Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease
| Autor: | Vera Bernet-Buettiker, Oliver Kretschmar, Manuela Albisetti, Alexander Moeller, Markus Schmugge, Urs Bauersfeld, Thomas Schraner, Joe Bontadelli |
|---|---|
| Přispěvatelé: | University of Zurich, Albisetti, Manuela |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Heart Defects
Congenital Male medicine.medical_specialty Cardiac Catheterization Heart disease medicine.drug_class medicine.medical_treatment Low molecular weight heparin 610 Medicine & health Critical Care and Intensive Care Medicine Intensive Care Units Pediatric 142-005 142-005 Cohort Studies Intensive care Outcome Assessment Health Care Medicine Humans Enoxaparin Cardiac catheterization Dalteparin sodium business.industry Coronary Thrombosis Anticoagulant Infant Newborn Anticoagulants Infant medicine.disease Thrombosis Surgery Anesthesia Female business 2706 Critical Care and Intensive Care Medicine Enoxaparin sodium Switzerland medicine.drug |
| Popis: | Objective: To investigate efficacy and safety of enoxaparin for catheter-related arterial thrombosis in infants with congenital heart disease. Design: Prospective observational study. Setting: Pediatric Intensive Care and Cardiology Unit at the University Children's Hospital of Zurich. Patients: Acohort of 32 infants aged 0-12 months treated with enoxaparin for catheter-related arterial thrombosis from 2002 to 2005. Measurements: Dose requirements of enoxaparin, resolution of thrombosis by Doppler ultrasound, and bleeding complications. Results: Catheter-related arterial thrombosis was located in the iliac/femoral arteries in 31 (97%) infants and aorta in 1 infant, and was related to indwelling catheters and cardiac catheterization in 17 (53%) and 15 (47%) cases, respectively. Newborns required increased doses of enoxaparin to achieve therapeutic anti-FXa levels (mean 1.62 mg/kg per dose) compared with infants aged 2-12 months (mean 1.12 mg/kg per dose; p = 0.0002). Complete resolution of arterial thrombosis occurred in 29 (91%) infants at amean of 23 days after initiation of enoxaparin therapy. Partial or no resolution was observed in 1 (3%) and 2 (6%) infants, respectively, at amean follow-up time of 4.3 months. Bleeding complications occurred in 1 (3%) infant. Conclusion: Enoxaparin is efficient and safe for infants with congenital heart disease and catheter-related arterial thrombosis, possibly representing avalid alternative to the currently recommended unfractionated heparin |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|